单中心109例慢性粒-单核细胞白血病患者的分子学特征分析

OBJECTIVE: To explore the molecular features of chronic myelomonocytic leukemia（CMML）. METHODS: According to 2022 World Health Organization（WHO 2022）classification, 113 CMML patients and 840 myelodysplastic syndrome（MDS）patients from March 2016 to October 2021 were reclassified, and the clinical and molecular features of CMML patients were analyzed. RESULTS: Among 113 CMML patients, 23（20.4％）were re-diagnosed as acute myeloid leukemia（AML）, including 18 AML with NPM1 mutation, 3 AML with KMT2A rearrangement, and 2 AML with MECOM rearrangement. The remaining 90 patients met the WHO 2022 CMML criteria. In addition, 19 of 840（2.3％）MDS patients met the WHO 2022 CMML criteria. At least one gene mutation was detected in 99％ of CMML patients, and the median number of mutations was 4. The genes with mutation frequency ≥10％ were: ASXL1（48％）, NRAS（34％）, RUNX1（33％）, TET2（28％）, U2AF1（23％）, SRSF2（21.1％）, SETBP1（20％）, KRAS（17％）, CBL（15.6％）and DNMT3A（11％）. Paired analysis showed that SRSF2 was frequently co-mutated with ASXL1（OR＝4.129, 95％ CI 1.481–11.510, Q＝0.007）and TET2（OR＝5.276, 95％ CI 1.979–14.065, Q＝0.001）. SRSF2 and TET2 frequently occurred in elderly（≥60 years）patients with myeloproliferative CMML（MP-CMML）. U2AF1 mutations were often mutually exclusive with TET2（OR＝0.174, 95％ CI 0.038–0.791, Q＝0.024）, and were common in younger（<60 years）patients with myelodysplastic CMML（MD-CMML）. Compared with patients with absolute monocyte count（AMoC）≥1×10(9)/L and <1×10(9)/L, the former had a higher median age of onset（60 years old vs 47 years old, P<0.001）, white blood cell count（15.9×10(9)/L vs 4.4×10(9)/L, P<0.001）, proportion of monocytes（21.5％ vs 15％, P＝0.001）, and hemoglobin level（86 g/L vs 74 g/L, P＝0.014）. TET2 mutations（P＝0.021）and SRSF2 mutations（P＝0.011）were more common in patients with AMoC≥1×10(9)/L, whereas U2AF1 mutations（P<0.001）were more common in patients with AMoC<1×10(9)/L. There was no significant difference in the frequency of other gene mutations between the two groups. CONCLUSION: According to WHO 2022 classification, nearly 20％ of CMML patients had AMoC<1×10(9)/L at the time of diagnosis, and MD-CMML and MP-CMML had different molecular features.